CAJ | 학술논문

目的：评价温脾补肾法对中晚期恶性肿瘤患者免疫功能调节的疗效。方法：选取明确诊断的中晚期恶性肿瘤患者，随机分为对照组和治疗组，对照组采用常规治疗方案，治疗组在此基础上联合温脾补肾中药治疗，疗程为3个月。观察和检测治疗前后临床疗效、临床症状积分、T淋巴细胞亚群、药物安全性指标。结果：对照组有效率及临床受益率为31.1%和71.1%，治疗组分别为54.2%和85.4%，治疗组优于对照组（P<0.05）；与对照组比较，治疗组对T淋巴细胞亚群具有明显的调节作用，在改善临床症状评分方面效果优于对照组（P<0.05）；中药运用未见明显不良反应。结论：温脾补肾法具有提高中晚期恶性肿瘤患者临床疗效、改善患者的生存质量、不良反应少的综合效果，其作用机制可能是通过对免疫功能的调节而实现。
목적：평개온비보신법대중만기악성종류환자면역공능조절적료효。방법：선취명학진단적중만기악성종류환자，수궤분위대조조화치료조，대조조채용상규치료방안，치료조재차기출상연합온비보신중약치료，료정위3개월。관찰화검측치료전후림상료효、림상증상적분、T림파세포아군、약물안전성지표。결과：대조조유효솔급림상수익솔위31.1%화71.1%，치료조분별위54.2%화85.4%，치료조우우대조조（P<0.05）；여대조조비교，치료조대T림파세포아군구유명현적조절작용，재개선림상증상평분방면효과우우대조조（P<0.05）；중약운용미견명현불량반응。결론：온비보신법구유제고중만기악성종류환자림상료효、개선환자적생존질량、불량반응소적종합효과，기작용궤제가능시통과대면역공능적조절이실현。
This study was aimed to evaluate impacts on immune regulation with spleen-strengthening and kidney-tonifying method among advanced malignant tumor patients. The enrolled advanced malignant tumor patients were randomly divided into the control group and the treatment group. The control group was treated with conventional treatment plan. The treatment group was treated with spleen-strengthening and kidney-tonifying Chinese herbs on the basis of conventional treatment plan for three months. Clinical effect, integral of clinical symptom (ICS), T-lym-phocyte subsets, and drug safety index were observed and detected before and after treatment. The results showed that the effective rate and response rate in the control group were 31.1% and 71.1%, respectively. And the effective rate and response rate in the treatment group were 54.2% and 85.4%, respectively. The treatment group was better than the control group (P< 0.05). Compared to the control group, the treatment group had obvious regulation on T-lymphocyte subsets. The improvement on ICS in the treatment group was better than the control group (P < 0.05). There was no obvious adverse reaction with the application of Chinese herbs. It was concluded that the spleen-strengthening and kidney-tonifying method can improve clinical effect, life of quality, and reduce adverse reaction a-mong advanced malignant tumor patients. Its mechanism may be through the regulation of immune function.